Patients with a clinical history of chronic Gastroesophageal Reflux Disease (GERD) already possess a severely inflamed, hyper-reactive lower esophagus (esophagitis)
Clinical outcomes with established injectable GLP-1 receptor agonists are well-documented
Tirzepatide May Be Considered When A physician determines that dual-receptor therapy may be appropriate based on weight, metabolic risk, prior treatment response, side-effect tolerance, and treatment goals
Scientific References Depommier C, Everard A, Druart C, et al
The GLP-1 patches advertised online are dietary supplements, not pharmaceuticals, and they contain none of the active GLP-1 drug ingredients like semaglutide or tirzepatide
Clues from laboratory models and clinical trials